Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | TOP2A | P11388 | 7/20 | 0.47 |
| ▸ | TOP2B | Q02880 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9094738 | 1.00 | ALDH1A1 (0.53) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| SCHEMBL967193 | 1.00 | ALDH1A1 (0.53) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| SCHEMBL500581 | 1.00 | ALDH1A1 (0.53) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| SCHEMBL28511779 | 0.89 | ALDH1A1 (0.52) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| SCHEMBL9096661 | 0.89 | TOP2A (0.53) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| SCHEMBL500455 | 0.89 | TOP2A (0.53) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| SCHEMBL7607382 | 0.89 | TOP2A (0.53) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| SCHEMBL12673591 | 0.88 | ALDH1A1 (0.51) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| SCHEMBL4747713 | 0.88 | ALDH1A1 (0.51) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| SCHEMBL7510943 | 0.88 | TOP2A (0.50) | ALDH1A1POLBCHRM2CHRM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7867992-B2 | such as 1-Cyclopropyl-N-(2,4-dichlorobenzyl)-6-fluoro-8-methoxy-7-[3-methyl-4-(2-{[(methylamino)carbonyl]amino}-2-oxoethyl)piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxamide, used for the treatment and/or prophylaxis of viral diseases or infections, particularly against cytomegaloviruses | AICURIS GMBH & CO. KG (DE) | 2011-01-11 | — | — | US | disclosed |
| US-RE41149-E1 | Stereoisomerically pure 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid or a pharmaceutically acceptable salt thereof; antibacterial agents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-02-23 | — | — | US | disclosed |
| US-RE41149-E1 | Stereoisomerically pure 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid or a pharmaceutically acceptable salt thereof; antibacterial agents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-02-23 | — | — | US | disclosed |
| US-20070293478-A1 | Substituted quinolones | BAYER HEALTHCARE AG (DE) | 2007-12-20 | — | — | US | disclosed |
| EP-1768973-B1 | SUBSTITUTED QUINOLONES | AICURIS GMBH & CO KG (DE) | 2007-12-05 | — | — | EP | disclosed |
| US-6018054-A | INTERMEDIATE COMPOUNDS FOR PREPARING NOVEL QUINOLONE AND NAPHTHYRIDONE DERIVATIVES WHICH ARE SUBSTITUTED IN THE 7-POSITION BY A PARTIALLY HYDROGENATED ISOINDOLINYL RING, USE AS ANTIBACTERIAL AGENTS AND AS FEED ADDITIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-01-25 | — | — | US | disclosed |
| EP-0705828-B1 | Quinolone- and naphthyridone carboxylic acid derivatives as antibacterial agents | BAYER AG (DE) | 1999-12-01 | — | — | EP | disclosed |
| US-5990122-A | SUBSTITUTED IN THE 7-POSITION BY A TRICYCLIC AMINE RADICAL; REDUCED GENOTOXIC PROPERTIES AND INCREASED ANTIBACTERIAL ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 1999-11-23 | — | — | US | disclosed |
| US-5783708-A | HEXAHYDROISOINDOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-07-21 | — | — | US | disclosed |
| US-5753669-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-05-19 | — | — | US | disclosed |
| US-5574161-A | GRAMPOSITIVE BACTERICIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1996-11-12 | — | — | US | disclosed |
| US-5556979-A | ANIMAL FEEDS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-09-17 | — | — | US | disclosed |
| US-5545642-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-08-13 | — | — | US | disclosed |
| EP-0721948-A1 | Quinolone- and naphthyridone carboxylic acid derivatives as antibacterial agents | BAYER AG (DE) | 1996-07-17 | — | — | EP | disclosed |
| EP-0705828-A1 | Quinolone- and naphthyridone carboxylic acid derivatives as antibacterial agents | BAYER AG (DE) | 1996-04-10 | — | — | EP | disclosed |
| WO-1996001262-A1 | NOVEL QUINOLINE COMPOUND AND PROCESS FOR PREPARATION THEREOF | HANMI PHARMACEUTICAL CO., LTD. (KR) | 1996-01-18 | — | — | WO | disclosed |
| EP-0589318-B1 | Antibacterial 7-(aminomethyl-oxa-7-azabicyclo(3.3.0)oct-7-yl)quinolone- and -naphthyridonecarboxylic acid derivatives | BAYER AG (DE) | 1995-11-15 | — | — | EP | disclosed |
| EP-0653425-A1 | 1-(2-Fluorocyclopropyl)-quinolone- and naphthyridone carboxylic acid derivatives, their preparation and their use as antibacterials | BAYER AG (DE) | 1995-05-17 | — | — | EP | disclosed |
| US-5395944-A | Bactericides | BAYER AKTIENGESELLSCHAFT (DE) | 1995-03-07 | — | — | US | disclosed |
| EP-0589318-A2 | Antibacterial 7-(aminomethyl-oxa-7-azabicyclo(3.3.0)oct-7-yl)quinolone- and -naphthyridonecarboxylic acid derivatives | BAYER AG (DE) | 1994-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293478-A1 | Substituted quinolones | IRF3, TPMT, NQO2 | ALDH1A1 2853/4885POLB 86/4885CHRM2 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.